Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Cancer Immunology, Immunotherapy

Issue 9/2001

Content (7 Articles)

Original Article

Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity

J. Li, L. Holmes, K. Franek, K. Burgin, T. Wagner, Y. Wei

Original Article

Dendritic cells pulsed with tumor extract–cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor

Hideo Aoki, Masaaki Mizuno, Atsushi Natsume, Takahiko Tsugawa, Kunio Tsujimura, Toshitada Takahashi, Jun Yoshida

Original Article

A TGFβRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells

Ingvil Sæterdal, Marianne K. Gjertsen, Per Straten, Jon A. Eriksen, Gustav Gaudernack

Original Article

Soluble ICAM-1 in breast cancer: clinical significance and biological implications

Wolfgang J. Köstler, Sandra Tomek, Thomas Brodowicz, Alexandra C. Budinsky, Maria Flamm, Michael Hejna, Michael Krainer, Christoph Wiltschke, Christoph C. Zielinski

Original Article

Biodistribution of 111indium-labeled macrophages infused intravenously in patients with renal carcinoma

Véronique Quillien, Annick Moisan, Thierry Lesimple, Claudine Leberre, Louis Toujas

Original Article

Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes

Elke S. Bergmann-Leitner, Scott I. Abrams

Original Article

Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma

Pontus Hegardt, Bengt Widegren, Li Li, Barbro Sjögren, Christian Kjellman, Inderpreet Sur, Hans Sjögren

Oct 01
Issue: 8/2001
Dec 01
Issue: 10/2001

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits